Editorial

Type 2 Diabetes and Hispanic Culture: Two Kinds of Insulin Resistance

Authors: Clifford D. Packer, MD

Abstract

Type 2 diabetes mellitus is an inexorably progressive disease. Over time, as insulin resistance increases and beta cell function declines, treatment with injected insulin becomes necessary for most patients to maintain euglycemia. In the landmark United Kingdom Prospective Diabetes Study (UKPDS), 53% of the patients who were started on a sulfonylurea drug required insulin treatment within six years, which correlates with known secondary sulfonylurea failure rates of 5% to 10% per year. Early insulin treatment was found to improve glycemic control and prevent complications when maximal sulfonylurea treatment was inadequate.1 Combination treatment with sulfonylurea plus other oral agents can delay progression to insulin dependence,2but the fact remains that most patients with type 2 diabetes will eventually require insulin and will suffer more complications if insulin is not started promptly when oral agents fail. This aspect of the natural history of type 2 diabetes has profound clinical and economic implications. About 120 million people worldwide were estimated to have type 2 diabetes in 2000; by 2010, the number may swell to 220 million.3 Among Hispanics, the prevalence of type 2 diabetes is twice that of non-Hispanic whites, and rates of end-stage renal disease and other serious complications are also significantly higher. Inadequate treatment for these patients as they progress to insulin dependence could seriously overburden our public health resources. It is therefore critical that physicians understand the many barriers—cultural, psychological, economic, and technical—that their patients face when advised to start insulin treatment.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Wright A, Burden AC, Paisey RB, et al, for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330–336.
 
2. Eurich DT, Simpson SH, Majumdar SR, et al. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005;25:810–816.
 
3. Shaw JE, Zimmet PZ, McCarty D, et al. Type 2 diabetes worldwide according to the new classification and criteria. Diabetes Care 2000;23 (Suppl 2):B5–10.
 
4. Campos C. Addressing cultural barriers to the successful use of insulin in Hispanics with type 2 diabetes. South Med J 2007;100:812–820.
 
5. Berlin EA, Fowkes WC Jr. A teaching framework for cross-cultural health care. Application in family practice. West J Med 1983;139:934–938.
 
6. Poss J, Jezewski MA. The role and meaning of susto in Mexican Americans' explanatory model of type 2 diabetes. Med Anthropol Q 2002;16:360–377.
 
7. Poss JE, Jezewski MA, Stuart AG. Home remedies for type 2 diabetes used by Mexican Americans in El Paso, Texas. Clin Nurs Res 2003;12:304–323.
 
8. Weller SC, Baer RD, Pachter LM. Latino beliefs about diabetes. Diabetes Care 1999;22:722–728.
 
9. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006;145:125–134.